Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Prothena Corporation plcNASDAQ: PRTA

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 54.11M shares rose 0.5% year over year, ahead of the -0.4% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at +4.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +0.5% holds above the trailing-twelve-month pace of -0.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
54.11M+0.5% QoQ
Last fiscal yearDec 2025
53.83M+0.1% YoY
LTMMar 2026
53.9M-0.4% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.5%——
1 year+0.1%——
3-year CAGR+4.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
53.83M USD
Year-over-year change
+0.1%
4-year CAGR
+2.7%

Weighted Avg Shares (Diluted) vs competitors

How PRTA compares with its peers on the latest reported figures

  • PRTA's LTM Mar 2026 weighted avg shares (diluted) of 53.9M shares is the 9th highest of the 10 companies compared; the peer median is 99.9M shares.
  • Its year-over-year change of -0.4% is the 9th highest of 10, against a peer median of +4.0%.
  • Over three fiscal years its annual growth of +4.4% compares with a peer median of +11.8%.
PRTA Competitors Peer median
Weighted Avg Shares (Diluted) for PRTA and competitors
Company Period LTM YoY 3-year CAGR
DNLIDenali Therapeutics Inc.LTM Jun 2026180.46M +5.8%+11.8%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
ANNXAnnexon, Inc.LTM Mar 2026161.69M +14.3%+41.6%
BIIBBiogen Inc.LTM Jun 2026147.73M +1.2%+0.2%
ACIUAC Immune S.A.LTM Mar 202699.9M -0.5%+6.4%
AVXLAnavex Life Sciences Corp.LTM Dec 202586.34M +2.9%+3.5%
CGTXCognition Therapeutics, Inc.LTM Mar 202679.93M +69.4%+35.9%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 202661.23M +1.8%+14.3%
PRTAProthena Corporation plcLTM Mar 202653.9M -0.4%+4.4%
PMNProMIS Neurosciences, Inc.LTM Jun 20264.71M +249.6%+80.2%
Peer median (excluding PRTA) 99.9M+4.0%+11.8%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue200.58M53.91M91.37M135.16M9.68M
Cost of Revenue00003.7M
Gross Profit200.58M53.91M91.37M135.16M5.98M
Gross Margin100.0%100.0%100.0%100.0%61.8%
Research & Development82.28M135.56M220.57M222.52M134.85M
Selling, General & Admin46.32M49.9M61.84M67.2M59.39M
Operating Expenses128.6M185.46M282.41M289.72M190.54M
Depreciation & Amortization1.12M744K928K893K3.7M
EBITDA73.04M(124.86M)(159.55M)(128.04M)(197.13M)
EBITDA Margin36.4%-231.6%-174.6%-94.7%-2035.6%
Operating Income71.98M(131.56M)(191.04M)(154.56M)(184.56M)
Operating Margin35.9%-244.1%-209.1%-114.4%-1905.8%
Interest Income42K6.35M31.01M25.82M14.14M
Interest Expense00000
Other Income / Expenses(54K)5.95M30.56M25.63M(16.27M)
Income Before Tax71.92M(125.61M)(160.48M)(128.93M)(200.83M)
Pre-Tax Margin35.9%-233.0%-175.6%-95.4%-2073.8%
Income Tax Expense4.95M(8.66M)(13.45M)(6.62M)43.26M
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Net Margin33.4%-217.0%-160.9%-90.5%-2520.6%
EPS (Basic)1.51(2.47)(2.76)(2.27)(4.53)
EPS (Diluted)1.38(2.47)(2.76)(2.27)(4.53)
Weighted Avg Shares44.23M47.37M53.22M53.77M53.83M
Weighted Avg Shares (Diluted)48.46M47.37M53.22M53.77M53.83M

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.